

OPTIMIZATION IN THE USE OF DRUGS FOR AGE-RELATED MACULAR DEGENERATION

J. González Chávez, R. Madera Pajin, C. Gallego Fernández, L. Yunquera Romero, I. Muñoz Castillo
Hospital Regional Universitario de Málaga, Málaga. Spain.

BACKGROUND:

Antiangiogenic drugs are the treatment of choice for age-related macular degeneration (AMD) which causes a high impact due to the high cost of vials and absence of commercially syringes with the necessary dose.

PURPOSE:

To compare the efficiency of alternative therapies available for the treatment of AMD

optimizing vials to prepare syringes with exact doses



Ranibizumab

Aflibercept

MATERIAL AND METHODS:

MAY 2013–MAY 2014


Aflibercept: 4 syringes of each vial
Not included in hospital yet

Ranibizumab: 3 syringes of each vial

Medical prescriptions

Computer records of the pharmacothecal unit

To compare treatments and efficiency, we have considered:
-The same patients
-The same number of syringes of aflibercept than ranibizumab



RESULTS:

151 patients ↔ 7,8 syringes/patient

	Syringes	Cost of syringes	Vials	Cost of vials
Ranibizumab	1179 (of 393 vials)	271.739'85 €	1179	815.219'55 €
Aflibercept	1179 (of 295 vials)	190.139'3 €	1179	759.912'66 €

The difference between treatments is 55.306'89 €

CONCLUSION:

The optimization of the ranibizumab and aflibercept vials saves money for the health system, as well as provides greater accuracy and safety when preparing these sterile syringes in the Pharmacy Service. Assuming the equivalence in effectiveness, we propose aflibercept like the most efficient therapy.